Eli Lilly & Co.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $7.10B | $7.40B | $6.64B | $5.58B | $5.66B | $2.76B | $4.41B | $970.3M |
| Depreciation & Amortization | $534.0M | $509.0M | $585.7M | $470.3M | $478.0M | $463.0M | $485.2M | $466.8M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $201.0M | $161.0M | $136.1M | $150.9M | $185.0M | $154.0M | $142.3M | $133.2M |
| Net Cash from Operating Activities | $10.69B | $5.33B | $3.22B | $8.84B | $3.09B | $1.67B | $2.47B | $3.71B |
| Investing Activities | ||||||||
| Capital Expenditures | $2.93B | $2.33B | $2.55B | $2.09B | $1.70B | $1.51B | $1.50B | $1.35B |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-15.40B | $-3.92B | $-2.80B | $-2.98B | $-1.83B | $-3.35B | $-1.92B | $-4.00B |
| Financing Activities | ||||||||
| Dividends Paid | $1.55B | $1.55B | $1.35B | $1.35B | $1.35B | $1.35B | $1.17B | $1.17B |
| Stock Repurchases | $1.60B | $2.36B | $1.51B | $708.3M | $692.0M | $1.20B | $2.05B | $446.1M |
| Net Cash from Financing Activities | $8.43B | $-3.47B | $-2.88B | $530.8M | $-1.25B | $1.38B | $-225.5M | $211.3M |
| Net Change in Cash | $3.67B | $-1.99B | $-2.52B | $6.42B | $283.0M | $-175.0M | $-101.4M | $145.4M |
| Free Cash Flow | $7.76B | $3.01B | $677.9M | $6.75B | $1.39B | $156.0M | $977.7M | $2.36B |